Causal Involvement of Immune Cells in Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Study
International Journal of Chronic Obstructive Pulmonary Disease · 2024
DOI: 10.2147/copd.s460342 ↗At a glance
Journal article in International Journal of Chronic Obstructive Pulmonary Disease, 2024. Written by Tiefa Guan and 3 co-authors. Institution: First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, People's Republic of China. Major MEDLINE topics: Pulmonary Disease, Chronic Obstructive, Mendelian Randomization Analysis, Genome-Wide Association Study, Genetic Predisposition to Disease. Cited 1 times so far (Crossref); 41 references. The full text is freely available (open access, CC BY-NC 3.0). Funded by: National Natural Science Foundation of China, Seedling project of the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine.
Topics: COPD
Abstract (original language)
Background
The immune cells play a substantial role in the development and progression of chronic obstructive pulmonary disease (COPD). We aim to investigate the causal involvement of immune cells in COPD via a Mendelian randomization (MR) analysis.
Methods
Published genome-wide association studies (GWAS) statistics on immune cells were analyzed, with genetic variants identified as instrumental variables (IVs). Inverse-variance weighting (IVW), weighted median, and MR-Egger regression methods were employed, along with simple mode and weighted mode adopted in the two-sample MR analysis. Sensitivity analysis was conducted to examine the heterogeneity, horizontal pleiotropy, and stability of the causal relationship.
Results
IVW results suggested that CCR2 on CD62L+ plasmacytoid dendritic cells (DC), CCR2 on plasmacytoid DC, CD11b on CD66b++ myeloid cells, CD19 on CD20- CD38- CD24+ memory B cell subset, CD25 on transitional B cells, and CD25++CD8br %CD8br T cells were risk factors for the development of COPD. Besides, CD127 on effector memory-like cytotoxic T lymphocytes lacking expression of co-stimulatory molecule 28 (CD28-EM CTLs) and HLA DR+ NK ACs expressing human leukocyte antigen DR molecules while being natural killer cells (%NK ACs) were protective factors for COPD.
Conclusion
This study unveiled a causal relationship between immune cell phenotype and COPD. These findings offer new insights for the prevention and treatment of COPD using COPD-associated immune cells.
Subjects
MeSH terms (MEDLINE)
Author keywords
Authors and institutions
- First Clinical College, Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, People's Republic of China.
- Department of Respiratory and Critical Care Medicine, the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, People's Republic of China.
- Department of Respiratory and Critical Care Medicine, Affiliated Hospital of Liaoning University of Traditional Chinese Medicine, Shenyang, Liaoning Province, People's Republic of China.
ORCID profiles: Tiefa Guan
Funding
- National Natural Science Foundation of China
- Seedling project of the Second Affiliated Hospital of Liaoning University of Traditional Chinese Medicine
Cite
APA
Guan, T., Qin, Y., Qu, N., & Pan, Y. (2024). Causal Involvement of Immune Cells in Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Study. International Journal of Chronic Obstructive Pulmonary Disease. https://doi.org/10.2147/copd.s460342
Vancouver
Guan T, Qin Y, Qu N, Pan Y. Causal Involvement of Immune Cells in Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Study. International Journal of Chronic Obstructive Pulmonary Disease. 2024. doi:10.2147/copd.s460342
BibTeX
@article{Guan2024,
author = {Guan, Tiefa and Qin, Yibing and Qu, Nini and Pan, Yushuo},
title = {Causal Involvement of Immune Cells in Chronic Obstructive Pulmonary Disease: A Mendelian Randomization Study},
journal = {International Journal of Chronic Obstructive Pulmonary Disease},
year = {2024},
doi = {10.2147/copd.s460342}
}
EUVIMED